BNP Paribas Financial Markets Raises Stake in UroGen Pharma Ltd. (NASDAQ:URGN)

BNP Paribas Financial Markets lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGNFree Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,996 shares of the company’s stock after purchasing an additional 6,617 shares during the period. BNP Paribas Financial Markets owned about 0.10% of UroGen Pharma worth $345,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in URGN. China Universal Asset Management Co. Ltd. grew its stake in UroGen Pharma by 361.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,575 shares of the company’s stock worth $54,000 after acquiring an additional 2,801 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in UroGen Pharma by 31.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock worth $74,000 after purchasing an additional 1,191 shares in the last quarter. SG Americas Securities LLC purchased a new position in UroGen Pharma during the 4th quarter worth $131,000. Federated Hermes Inc. bought a new stake in UroGen Pharma during the 3rd quarter valued at $184,000. Finally, Jump Financial LLC bought a new stake in UroGen Pharma during the 3rd quarter valued at $415,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Analyst Ratings Changes

URGN has been the subject of several recent research reports. Oppenheimer decreased their price objective on UroGen Pharma from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th. HC Wainwright reiterated a “buy” rating and set a $54.00 price objective on shares of UroGen Pharma in a research note on Tuesday, May 14th.

View Our Latest Stock Report on UroGen Pharma

UroGen Pharma Price Performance

Shares of URGN stock opened at $13.08 on Wednesday. The company has a market cap of $306.73 million, a P/E ratio of -3.85 and a beta of 1.08. The stock’s 50-day moving average is $13.74 and its 200 day moving average is $14.95. UroGen Pharma Ltd. has a 1-year low of $8.69 and a 1-year high of $24.13.

UroGen Pharma (NASDAQ:URGNGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.04). The company had revenue of $18.78 million for the quarter, compared to analysts’ expectations of $20.73 million. On average, analysts anticipate that UroGen Pharma Ltd. will post -3.6 EPS for the current year.

Insider Activity

In related news, insider Mark Schoenberg sold 12,000 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the transaction, the insider now directly owns 139,437 shares in the company, valued at approximately $1,959,089.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 11.13% of the company’s stock.

UroGen Pharma Company Profile

(Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Featured Articles

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UroGen Pharma Ltd. (NASDAQ:URGNFree Report).

Institutional Ownership by Quarter for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.